-98.4%
NVD vs GSK
+60.8%
-159.2%
-99.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | -2.3% | +3.2% | +1.3% |
| 7D | +16.5% | -3.0% | +19.6% | +17.3% |
| 30D | +76.6% | +0.4% | +76.3% | +76.4% |
| 3M | +85.2% | -1.2% | +86.4% | +85.4% |
| 6M | +68.4% | +0.9% | +67.5% | +68.4% |
| YTD | +1.5% | +4.0% | -2.5% | 0.0% |
| 1Y | -0.9% | +7.3% | -8.2% | -2.8% |
| 3Y | -98.2% | +57.1% | -155.2% | -98.2% |
| All | -98.4% | +60.8% | -159.2% | -98.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling